These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16900222)

  • 1. Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent.
    Tang S; Lai KN
    Kidney Int; 2006 Aug; 70(4):818. PubMed ID: 16900222
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy?
    Ng YY; Yang WC; Lee ST
    Kidney Int; 2006 Feb; 69(4):776. PubMed ID: 16518335
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy.
    Chuang TW; Hung CH; Huang SC; Lee CM
    J Formos Med Assoc; 2007 Oct; 106(10):869-73. PubMed ID: 17964968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine.
    Filler G; Feber J; Weiler G; Le Saux N
    Arch Dis Child; 2003 May; 88(5):460. PubMed ID: 12716731
    [No Abstract]   [Full Text] [Related]  

  • 7. Lamivudine and HBV-associated nephropathy.
    Izzedine H; Massard J; Poynard T; Deray G
    Nephrol Dial Transplant; 2006 Mar; 21(3):828-9. PubMed ID: 16263733
    [No Abstract]   [Full Text] [Related]  

  • 8. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy.
    Yang Y; Ma YP; Chen DP; Zhuo L; Li WG
    PLoS One; 2016; 11(9):e0160437. PubMed ID: 27598699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing clinical development programs for anti-hepatitis B virus drugs.
    Brown NA
    Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
    Tanaka E; Matsumoto A; Yoshizawa K; Maki N
    Intervirology; 2008; 51 Suppl 1():3-6. PubMed ID: 18544941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of hepatitis B virus associated nephrotic syndrome with oral Lamivudine in a Nigerian child: a case report.
    Ladapo TA; Onifade EU; Lesi AE; Lesi OA
    J Trop Pediatr; 2012 Apr; 58(2):157-8. PubMed ID: 21624925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of sulodexide might be associated with inhibition of complement system in hepatitis B virus-associated membranous nephropathy: An inspiration from a pilot trial.
    Yang Y; Ma L; Wang C; Kong D; Wang Y; Mei C
    Eur J Intern Med; 2016 Jul; 32():96-104. PubMed ID: 27160380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy.
    Chen L; Zhang Q; Yu DM; Wan MB; Zhang XX
    J Hepatol; 2009 May; 50(5):895-905. PubMed ID: 19304333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B.
    Janssen HL; van Zonneveld M; Schalm SW
    N Engl J Med; 2004 Jun; 350(26):2719-20. PubMed ID: 15215493
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hepatitis B virus-associated membranous glomerulonephritis with interferon alfa in a 7 year old boy].
    Steiss JO; Piske-Keyser K; Gröne HJ; Gortner L
    Klin Padiatr; 2000; 212(5):283-6. PubMed ID: 11048290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
    Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
    Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advance in clinical studies of the kinetics of hepatitis B virus].
    Tang YT; Cao Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
    [No Abstract]   [Full Text] [Related]  

  • 20. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.
    Ayres A; Yuen L; Jackson KM; Manoharan S; Glass A; Maley M; Yoo W; Hong SP; Kim SO; Luciani F; Bowden DS; Bayliss J; Levy MT; Locarnini SA
    J Viral Hepat; 2014 Nov; 21(11):809-17. PubMed ID: 24329944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.